CD274 and neoplasm: Tumor expression of programmed death ligand-1 (PD-L1) has been shown to be associated with the efficacy of immune checkpoint inhibitors in patients with non-squamous NSCLC [8], whereas immune checkpoint inhibitors are known to be less effective in patients with EGFR-mutant NSCLC [9,10].